Disc Medicine CLO granted RSUs and options

Disc Medicine's Chief Legal Officer, Rahul Khara, reported new equity awards in the company’s stock.

Rhea-AI Filing Summary

Disc Medicine's Chief Legal Officer, Rahul Khara, reported new equity awards in the company’s stock. On February 10, 2026, he acquired 17,000 shares of Common Stock as restricted stock units granted at $0 cost. These RSUs vest in four annual 25% installments starting February 15, 2027, contingent on continued service.

He was also granted a stock option for 25,500 shares of Common Stock at an exercise price of $74.75 per share, vesting in 48 equal monthly installments beginning March 10, 2026. Following these awards, he directly owned 55,026 Common shares and 25,500 option shares.

Insider Trade Summary

Grant/Award: 42,500 shares

Grant/Award 2 txns

Insider Khara Rahul

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	25,500	$0.00	$0.00
Grant/Award	Common Stock	17,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 25,500 contracts (Direct); Common Stock — 55,026 shares (Direct)

Footnotes (3)

1. F1. Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest annually in four 25% installments commencing on February 15, 2027, subject to the Reporting Person's continued service on each such vesting date.
2. F2. Includes 233 shares purchased pursuant to the Disc Medicine, Inc. Amended and Restated 2021 Employee Stock Purchase Plan on January 30, 2026.
3. F3. The shares underlying this option vest in 48 equal monthly installments commencing on March 10, 2026, subject to the Reporting Person's continued service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IRON’s Chief Legal Officer report on this Form 4?

Rahul Khara, Disc Medicine’s Chief Legal Officer, reported equity awards granted on February 10, 2026. He received 17,000 restricted stock units and a stock option for 25,500 shares, both as compensation awards rather than open-market purchases or sales.

How many Disc Medicine (IRON) shares did Rahul Khara acquire directly?

He acquired 17,000 shares of Common Stock in the form of restricted stock units. These RSUs represent a right to receive one share each and vest over four years, subject to his continued service with Disc Medicine on specified vesting dates.

What are the terms of the stock option granted to IRON’s Chief Legal Officer?

The stock option covers 25,500 shares of Disc Medicine Common Stock with a $74.75 exercise price. It vests in 48 equal monthly installments starting March 10, 2026, so long as Rahul Khara continues his service with the company during the vesting period.

What is Rahul Khara’s ownership in Disc Medicine (IRON) after these transactions?

After the February 10, 2026 awards, he directly beneficially owned 55,026 shares of Disc Medicine Common Stock, including 233 shares from the company’s 2021 Employee Stock Purchase Plan, plus 25,500 stock option shares subject to vesting and future exercise.

How do the restricted stock units for IRON’s Chief Legal Officer vest?

The 17,000 RSUs vest annually in four equal 25% installments, beginning February 15, 2027. Each vesting date requires that Rahul Khara remain in continued service with Disc Medicine, after which vested RSUs convert into shares of Common Stock.

Are the equity awards to IRON’s Chief Legal Officer immediate cash transactions?

No, both awards are compensation-based equity grants. The RSUs cost $0 at grant and convert into shares over time, while the option also costs $0 at grant but requires payment of the $74.75 exercise price per share if exercised in the future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 07:50 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Khara Rahul

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		A		17,000(1)	A	$0	55,026(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$74.75	02/10/2026		A		25,500		(3)	02/09/2036	Common Stock	25,500	$0	25,500	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest annually in four 25% installments commencing on February 15, 2027, subject to the Reporting Person's continued service on each such vesting date.

2. Includes 233 shares purchased pursuant to the Disc Medicine, Inc. Amended and Restated 2021 Employee Stock Purchase Plan on January 30, 2026.

3. The shares underlying this option vest in 48 equal monthly installments commencing on March 10, 2026, subject to the Reporting Person's continued service on each such vesting date.

	By: /s/ Rahul Khara	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.